U.S., Dec. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07265206) titled 'A Study of HY001N in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases' on Nov. 17.
Brief Summary: This study is a single-arm, open-label, non-randomized clinical trial aimed at evaluating the safety, tolerability and preliminary efficacy of HY001N cell injection in the treatment of patients with relapsed/refractory Neurological Autoimmune Diseases.
Study Start Date: Dec. 30
Study Type: INTERVENTIONAL
Condition:
Neurological Autoimmune Diseases
Intervention:
BIOLOGICAL: HY001N cell injection
A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investiga...